Российский биотерапевтический журнал

Расширенный поиск

Метаболизм железа, ферроптоз, рак

Полный текст:


В 2012 г. была описана новая, железозависимая форма клеточной гибели - ферроптоз, отличающаяся по морфологическим, биохимическим и генетическим особенностям от апоптоза, аутофагии и программируемого некроза. В обзоре обсуждаются вопросы метаболизма железа в норме и при злокачественных новообразованиях, молекулярные характеристики ферроптоза и возможности терапии онкологических больных в свете новых данных.

Об авторе

А. А. Вартанян
ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России

Список литературы

1. Kleingardner J.G., Bren K.L. Biological significance and applications of heme proteins and peptides. Acc Chem Res 2015;48(7):1845-52. DOI: 10.1021/acs. accounts.5b00106. PMID: 26083801.

2. Zhang D.L., Ghosh M.C., Rouault T.A. The physiological functions of iron regulatory proteins in iron homeostasis - an update. Frontiers in pharmacology 2014;5:124-129. PMID: 24982634.

3. Munoz M., Villar I., Garcia-Erce J.A. An update on iron physiology. World journal of Gastroenterology 2009;15:4617-4626. PMID: 19787824.

4. Soares M.P., Weiss G. The Iron age of host-microbe interactions. EMBO Rep 2015;16(11):1482-500. DOI: 10.15252/embr. 201540558. PMID: 26474900.

5. Li K., Reichmann H. Role of iron in neurodegenerative diseases. J Neural Transm (Vienna) 2016;123(4):389-99. DOI: 10.1007/s00702-016-1508-7. PMID: 26794939.

6. Yevenes A. The ferritin superfamily. Subcell Biochem 2017;83:75-102. DOI: 10.1007/978-3-319-46503-6-3. PMID: 28271473.

7. Wang J., Pantopoulos K. Regulation of cellular iron metabolism. Biochem J 2011;434:365-381. PMID: 21348856.

8. Dixon S.J., Stockwell B.R. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012;49:1060-1072. PMID: 22632970.

9. Xie Y., Hou W., Song X. et al. Ferroptosis: process and function. Cell Death Differ 2016;23:369-379. DOI: 10.1038/cdd.2015.158. PMID: 26794443.

10. Wallace D.F. The Regulation of Iron Absorption and Homeostasis. Clin Biochem Rev 2016;37(2):51-62. PMID: 28303071.

11. Reichert C.O., da Cunha J., Levy D. et al. Hepcidin: Homeostasis and Diseases Related to Iron Metabolism. Acta Haematol 2017;137(4):220-236. DOI: 10.1159/000471838. PMID: 28514781.

12. Ludwig H., Evstatiev R., Kornek G. et al. Iron metabolism and iron supplementation in cancer patients. Wien Klin Wochenschr 2015;127(23-24):907-19. DOI: 10.1007/ s00508-015-0842-3. PMID: 26373748.

13. Kabat G.C., Rohan T.E. Does excess iron play a role in breast carcinogenesis? An unresolved hypothesis. Cancer Causes Control 2007;18(10):1047-53. PMID: 17823849.

14. Gozzelino R., Arosio P. Iron Homeostasis in Health and Disease. Int J Mol Sci 2016;17(1):E130 - E138. DOI: 10.3390/ijms17010130. PMID: 26805813.

15. Drakesmith H., Nemeth E., Ganz T. Ironing out Ferroportin. Cell metabolism 2015;22(5):777-87. DOI: 10.1016/j.cmet.2015.09.006. PMID: 26437604.

16. Kew M.C. Hepatic iron overload and hepatocellular carcinoma. Liver Cancer 2014;3(1):31-40. DOI: 10.1159/000343856. PMID: 24804175.

17. Dolma S., Lessnick S.L., Hahn W.C. et al. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 2003;3:285-96. PMID: 12676586.

18. Yang W.S., Stockwell B.R. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol 2008;15:234-45. PMID: 18355723.

19. Bedford M.R., Ford S.J., Horniblow R.D. et al. Iron chelation in the treatment of cancer: a new role for deferasirox? J Clin Pharmacol 2013;53(9):885-91. DOI: 10.1002/jcph.113. PMID: 23740857.

20. Dixon S.J. Ferroptosis: bug or feature? Immunol Rev 2017;277(1):150-7. DOI: 10.1111/imr.12533. PMID: PMID:28462529.

21. Meister A. Glutathione metabolism. Methods Enzymol 1995;251:3-7. PMID: 7651209.

22. Brigelius-Flohe R., Maiorino M. Glutathione peroxidases. Biochim Biophys Acta 2013;1830:3289-303. PMID: 23201771.

23. Kidane T.Z., Sauble E., Linder M.C. Release of iron from ferritin requires lysosomal activity. Am J Physiol Cell Physiol 2006;291:C445-55. DOI: 10.1152/ajpcell.00505.2005.

24. Terman A., Kurz T. Lysosomal iron, iron chelation, and cell death. Antioxid Redox Signal 2013;18(8):888-98. DOI: 10.1089/ars.2012.4885. PMID: 22909065.

25. Yagoda N., von Rechenberg M., Zaganjor E. et al. RAS-RAFMEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 2007;447:864-8. DOI: 10.1038/nature05859. PMID: 17568748.

26. Cao J.Y., Dixon S.J. Mechanisms of ferroptosis. Cell Mol Life Sci 2016;73:2195-209. DOI: 10.1007/s00018-016-2194. PMID: 27048822.

27. Fonseca-Nunes A., Jakszyn P., Agudo A. Iron and cancer risk - a systematic review and meta-analysis of the epidemiological evidence. Cancer Epidemiol Biomarkers Prev 2014;23:12-31. PMID: 24243555.

28. Turner N.D., Lloyd S.K. Association between red meat consumption and colon cancer: A systematic review of experimental results. Exp Biol Med(Maywood) 2017;42(8):813-39. DOI: 10.1177/1535370217693117. PMID: 28205448.

29. Corce V., Gouin S.G., Renaud S. et al. Recent advances in cancer treatment by iron chelators. Bioorg Med Chem Lett 2016;26(2):251-6. DOI: 10.1016/j.bmcl.2015.11.094. PMID: 26684852.

30. Zacharski L.R., Chow B.K., Howes P.S. et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008;100(14):996-1002. DOI: 10.1093/jnci/djn209. PMID: 18612130.

31. Durigova A., Jacot W., Pouderoux S. et al. Iron metabolism in breast cancer: knowledge and future. Ann Biol Clin (Paris) 2012;70(4):387-96. PMID: 22796610.

32. Xue D., Zhou C.X., Shi Y.B. et al. Decreased expression of ferroportin in prostate cancer. Oncol Lett 2015;10(2):913-6. PMID: 26622594.

33. Wang Q., Zhou J., Zhong D. et al. Ferroportin in the progression and prognosis of hepatocellular carcinoma. Eur J Med Res 2013. DOI: 10.1186/2047-783X-18-59. PMID: 24360312.

34. Nicolae C.D., Coman O.A., Ene C. et al. Hepcidin in neoplastic disease. J Med Life 2013;15;6(3):355-60. PMID: 24146699.

35. Yu H., Guo P., Xie X. et al. Ferroptosis, a new form of cell death, and its relationships with tumourous diseases. J Cell Mol Med 2017;21(4):648-57. DOI: 10.1111/jcmm.13008. PMID: 27860262.

36. Ivanov S.D., Semenov A. L., Mikhelson V.M. et al. Effects of iron ion additional introduction in radiation therapy of tumor-bearing animals. Radiats Biol Radioecol 2013;53(3): 296-303. PMID: 24450211.

37. Daniels T.R., Delgado T., Helguera G. et al. The transferrin receptor: targeted delivery of therapeutic agents into cancer cells. Clinical immunology (Orlando, Fla) 2006;121:159-76. PMID: 16920030.

38. Daniels T. R., Delgado T., Rodriguez J.A. et al. The transferrin receptor: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 2006; 121(2):144-58. PMID: 16904380.

39. Kiessling M.K., Klemke C.D., Kaminski M.M. et al. Inhibition of constitutively activated NF-kB induces ROS- and iron dependent cell death in cutaneous T cell lymphoma. Cancer Res 2009;69(6):2365-74. DOI: 10.1158/0008-5472. PMID: 19258503.

40. Lachaier E., Louandre C., Godin C. et al. Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors. Anticancer Res 2014;34:6417-22. FMID: 25368241.

41. Ohara T., Noma K., Urano S. et al. A novel synergistic effect of iron depletion on antiangiogenic cancer therapy. Int J Cancer 2013;132(11): 2705-13. DOI: 10.1002/ijc.27943. PMID: 23161652.

42. Kitamura H., Koike S., Nakazawa K. et al. A reversal in the vascularity of metastatic liver tumors from colorectal cancer after the cessation of chemotherapy plus bevacizumab: contrast-enhanced ultrasonography and histological examination. J Surg Oncol 2013;107(2):155-9. DOI: 10.1002/jso.23244. PMID: 22903532.

43. Schonberg D.L., Miller T.E., Wu Q. et al. Preferential Iron Trafficking Characterizes Glioblastoma Stem-like Cells. Cancer Cell 2015;28:441-55. PMID: 26461092.

44. Green D.R., Victor B. The pantheon of the fallen: why are there so many forms of cell death? Trends Cell Biol 2012;22:555-6. DOI: 10.1016/j.tcb.2012.08.008. PMID: 22995729.


Для цитирования:

Вартанян А.А. Метаболизм железа, ферроптоз, рак. Российский биотерапевтический журнал. 2017;16(3):14-20.

For citation:

Vartanian A.A. Iron metabolism, ferroptosis and cancer. Russian Journal of Biotherapy. 2017;16(3):14-20. (In Russ.)

Просмотров: 590

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 1726-9784 (Print)
ISSN 1726-9792 (Online)